Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
20 Janeiro 2021 - 3:00AM
Business Wire
Regulatory News:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210119005966/en/
Gwenan White, Executive Vice President,
Communications and Public Affairs, Ipsen (Photo: Business Wire)
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the
appointment of Gwenan White as Executive Vice President,
Communications and Public Affairs, effective March 2021. Based in
Boulogne, France, she will be responsible for designing,
implementing and managing the communications and public affairs
strategy for Ipsen at global level, reporting directly to David
Loew, CEO, Ipsen. Gwenan will serve on the Executive Leadership
Team.
“Along with the ELT, we are very pleased to welcome Gwenan to
Ipsen. She will be critical to the implementation of our new
strategy, Focus. Together. For patients & society. Her
background in communications and public affairs will help reinforce
Ipsen’s position as partner and employer of choice and will
contribute to developing the share-of-voice of our innovative
medicines. We look forward to working closely with her,” said David
Loew, CEO, Ipsen.
“I’m excited to join Ipsen at this key moment,” said Gwenan
White. “I look forward to further building Ipsen’s relationships
and engagement with institutions and stakeholders worldwide,
ensuring the strategic alignment of its communications and boosting
the visibility of its brands.”
Prior to joining Ipsen, Gwenan was the Global Head of Pharma
Communications and Patient Advocacy at Novartis Pharmaceuticals.
Over the course of her career, she has held a variety of roles in
public affairs, corporate, science and product communications,
patient advocacy and marketing at AbbVie, GSK and Schering
Plough.
Gwenan is a graduate of the University of Liverpool in BSc
(Hons) Biochemistry in 1990.
She will be based in Boulogne - France.
About Ipsen Ipsen is a global specialty-driven
biopharmaceutical group focused on innovation and Specialty Care.
The Group develops and commercializes innovative medicines in three
key therapeutic areas – Oncology, Neuroscience and Rare Diseases.
Its commitment to oncology is exemplified through its growing
portfolio of key therapies for prostate cancer, neuroendocrine
tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has
a well-established Consumer Healthcare business. With total sales
over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over
115 countries, with a direct commercial presence in more than 30
countries. Ipsen’s R&D is focused on its innovative and
differentiated technological platforms located in the heart of the
leading biotechnological and life sciences hubs (Paris-Saclay,
France; Oxford, UK; Cambridge, US). The Group has about 5,700
employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and
in the United States through a Sponsored Level I American
Depositary Receipt program (ADR: IPSEY). For more information on
Ipsen, visit www.ipsen.com.fr.
Ipsen’s Forward Looking Statement The forward-looking
statements, objectives and targets contained herein are based on
the Group’s management strategy, current views and assumptions.
Such statements involve known and unknown risks and uncertainties
that may cause actual results, performance or events to differ
materially from those anticipated herein. All of the above risks
could affect the Group’s future ability to achieve its financial
targets, which were set assuming reasonable macroeconomic
conditions based on the information available today. Use of the
words "believes", "anticipates" and "expects" and similar
expressions are intended to identify forward-looking statements,
including the Group’s expectations regarding future events,
including regulatory filings and determinations. Moreover, the
targets described in this document were prepared without taking
into account external growth assumptions and potential future
acquisitions, which may alter these parameters. These objectives
are based on data and assumptions regarded as reasonable by the
Group. These targets depend on conditions or facts likely to happen
in the future, and not exclusively on historical data. Actual
results may depart significantly from these targets given the
occurrence of certain risks and uncertainties, notably the fact
that a promising product in early development phase or clinical
trial may end up never being launched on the market or reaching its
commercial targets, notably for regulatory or competition reasons.
The Group must face or might face competition from generic products
that might translate into a loss of market share. Furthermore, the
Research and Development process involves several stages each of
which involves the substantial risk that the Group may fail to
achieve its objectives and be forced to abandon its efforts with
regards to a product in which it has invested significant sums.
Therefore, the Group cannot be certain that favorable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will
be sufficient to demonstrate the safe and effective nature of the
product concerned. There can be no guarantees a product will
receive the necessary regulatory approvals or that the product will
prove to be commercially successful. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the
forward-looking statements. Other risks and uncertainties include
but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of pharmaceutical
industry regulation and health care legislation; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the Group's ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the Group’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The Group is dependent on prices set for drugs, pricing and
reimbursement reforms and is vulnerable to the potential withdrawal
of certain drugs from the list of reimbursable products by
governments, and the relevant regulatory authorities in its
locations. In light of the economic crisis caused by the COVID-19
pandemic, there could be increased pressure on the pharmaceutical
industry to lower drug prices. The Group also depends on third
parties to develop and market some of its products which could
potentially generate substantial royalties; these partners could
behave in such ways which could cause damage to the Group’s
activities and financial results. The Group cannot be certain that
its partners will fulfil their obligations. It might be unable to
obtain any benefit from those agreements. A default by any of the
Group’s partners could generate lower revenues than expected. Such
situations could have a negative impact on the Group’s business,
financial position or performance. The Group expressly disclaims
any obligation or undertaking to update or revise any
forward-looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions,
assumptions or circumstances on which any such statements are
based, unless so required by applicable law. The Group’s business
is subject to the risk factors outlined in its registration
documents filed with the French Autorité des Marchés Financiers.
The risks and uncertainties set out are not exhaustive and the
reader is advised to refer to the Group’s 2019 Universal
Registration Document available on its website www.ipsen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005966/en/
Media Fanny Allaire Global Communications Director
+33(0)1 58 33 58 96 fanny.allaire@ipsen.com
Financial Community Eugenia Litz Vice President, Investor
Relations +44 (0) 1753 627721 eugenia.litz@ipsen.com
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Ipsen (EU:IPN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024